Trelstar Articles
Ipsen's revenues up 6% on new US launches
9 February 2009
US FDA accepts Debiopharm's Trelstar NDA for filing
24 November 2008
Ipsen's nine-month sales increase 7%
10 November 2008
Ipsen files for EU approval of six-month Decapeptyl
29 September 2008
Ipsen's first-half 2008 profit jumps 42%
8 September 2008
Ipsen's first-half sales beat expectations
11 August 2008
Ipsen's 2007 operating profit climbs 12%
10 March 2008
Six-month Decapeptyl similar to present forms
18 February 2008
Watson's 3rd-qtr 2007 revenue hits $594.7M
19 November 2007
Ipsen and Debiopharm extend Decapeptyl accord
5 November 2007
Watson's Trelstar is launched in USA
11 April 2005
Watson and Debiopharm sign deal for urology drugs
4 October 2004
Pfizer return another Pharmacia-licensed compound, Trelstar, to originator Debiopharm
8 December 2003
Debiopharm provides funding for Tulane Univ cancer research
3 February 2003
Showing 1-18 of 18 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
